NCT05509790View on ClinicalTrials.gov

A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 9, 2022

Primary Completion Date

February 18, 2024

Study Completion Date

December 31, 2026

Conditions
Breast Neoplasms
Interventions
DRUG

LY3484356

Administered orally.

Trial Locations (4)

201315

Fudan University Shanghai Cancer Center, Shanghai

241001

Wannan Medical College Yijishan Hospital, Wuhu

330025

The Third Hospital of Nanchang, Nanchang

410013

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY